[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multimodal-analgesia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multimodal-analgesia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,44,78,115,143,171,201,224,259],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100642944","comparison-of-the-rhomboid-intercostal-block-and-serratus-posterior-superior-intercostal-plane-block-100642944",false,"NCT07650877","Comparison of the Rhomboid Intercostal Block and Serratus Posterior Superior Intercostal Plane Block","Comparison of the Effects of Ultrasound-Guided Rhomboid Intercostal Block and Serratus Posterior Superior Intercostal Plane Block on Postoperative Acute Pain in Patients Undergoing Video-Assisted Thoracoscopic Surgery","Inclusion Criteria:\n\n* Patients undergoing elective VATS\n* Patients aged 18-75 years\n* Patients with ASA (American Society of Anesthesiologists) class I-III\n* Patients who have given informed consent\n\nExclusion Criteria:\n\n* Patients allergic to local anesthetics\n* Patients with bleeding disorders or those undergoing anticoagulant therapy\n* Pregnant and breastfeeding women\n* Patients with impaired consciousness, inability to communicate, or mental\u002Fcognitive impairment\n* Patients who refuse block application\n* Patients with infection in the area where the block will be applied","ALL","18 Years","75 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","Video-assisted thoracic surgery (VATS) is widely performed for the management of various thoracic pathologies and is generally associated with reduced surgical trauma compared with open thoracotomy. Nevertheless, patients may still experience considerable postoperative pain, which can adversely affect respiratory function, mobilization, and recovery. Various regional analgesic techniques have been incorporated into multimodal pain management strategies for VATS, including thoracic paravertebral block (TPVB), erector spinae plane block (ESPB), intercostal nerve block, serratus anterior plane block (SAPB), rhomboid intercostal block (RIB), and serratus posterior superior intercostal plane block (SPSIPB). Among these approaches, ultrasound-guided TPVB has traditionally been regarded as a reference regional analgesic technique. More recently, interfascial plane blocks have gained increasing attention because of their technical simplicity and favorable safety profile. RIB and SPSIPB are two novel interfascial plane blocks that may provide effective postoperative analgesia following thoracic surgery. The present study aims to compare the analgesic efficacy of RIB and SPSIPB in patients undergoing VATS and to evaluate their impact on postoperative pain outcomes.",[27,28,29,30,31],"Pain, Postoperative","Multimodal Analgesia","Rhomboid Intercostal Block","Serratus Posterior Superior Intercostal Plane Block","Thoracic Surgery, Video-Assisted","RECRUITING","2026-06-15",{"date":35,"type":36},"2026-06-16","ACTUAL",{"date":33,"type":36},{"date":39,"type":21},"2026-11-30",{"name":41,"class":42},"Ankara City Hospital Bilkent","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100642199","phase-3-assessing-suzetrigine-for-pain-reduction-following-ureteroscopic-surgery-100642199","NCT07654296","Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery","Multimodal Analgesia Pathway Assessing Role of Suzetrigine for the Reduction of Opioid Use Following Ureteroscopic Surgery","Inclusion Criteria:\n\n* Patients undergoing ureteroscopy between ages 21 to 80 at BWFH (Brigham \\& Women's Faulkner Hospital) by one of the department's high volume endoscopic surgeons. Patient who are or not pre-stented prior to surgery will be included (these will be assessed via stratification within a secondary analysis).\n* Patients able to consent for their own medical care (i.e. consent able to be obtained directly from patient and does not require a healthcare proxy or guardian)\n\nExclusion Criteria:\n\n* Regular opioid use prior to surgery or significant substance abuse concerns.\n* Inability of patient to provide their own consent (i.e. lack capacity).","21 Years","80 Years",{"count":54,"type":21},100,[56],"PHASE3","Urologic surgery has advanced with new technologies to allow less invasive management of common afflictions such as kidney stones, these procedures are notoriously painful as the ureter must be dilated to accommodate any instruments, and a ureteral stent is often left following surgery to allow for adequate healing. Unfortunately, stents are poorly tolerated by a significant number of patients, with up to 100% complaining of bothersome pain and 10% of patients with unplanned healthcare visits. Further complicating kidney stone management is the frequency of concurrent chronic kidney disease (CKD) or acute kidney injury (AKI) that prohibits many patients from taking NSAIDs which limits pain management options. There is now a push to treat these patients with multimodal analgesia to provide better care and reduce opioid use. Suzetrigine is a new a first-in-class selective inhibitor of the NaV1.8 sodium channel that functions as a non-opioid analgesic developed to treat acute pain and neuropathic pain. This study assesses the addition of suzetrigine to standard-of-care multimodal analgesia. We hypothesize a demonstrated decrease in opioid use, decrease Emergency Room visits within 30 days, decrease the number of unplanned care encounters.",[59,28,60,61,62],"Opioid Consumption, Postoperative","Ureteroscopy","Ureteral Stents","Ureteral Stent-Related Symptoms",[28,64,65,66],"Postoperative Opioid Consumption","ureteroscopy","ureteral stents","NOT_YET_RECRUITING","2026-06-12",{"date":70,"type":36},"2026-06-17",{"date":72,"type":21},"2026-08-01",{"date":74,"type":21},"2027-03-31",{"name":76,"class":42},"Brigham and Women's Hospital",2,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":43},"100610370","phase-3-suzetrigine-in-total-hip-arthroplasty-100610370","NCT07226700","Suzetrigine in Total Hip Arthroplasty","A Randomized, Placebo-controlled, Double-blind Trial of Suzetrigine in Total Hip Arthroplasty","Inclusion Criteria:\n\n* Patients undergoing primary THA (posterior approach) with participating surgeons\n* Age 18 to 80 years old\n* Planned discharge to home\n* Planned use of neuraxial anesthesia\n* American Society of Anesthesiologists (ASA) Physical Status 1 - 3\n\nExclusion Criteria:\n\n* ASA greater than 3\n* Chronic opioid use (daily MME of greater than 30 mg for at least 3 months and within 1 month of surgery)\n* History of chronic pain syndromes or uncontrolled pain (i.e. complex regional pain syndrome, fibromyalgia, implanted spinal cord stimulator)\n* History of QT prolongation\n* Presence of automated implantable cardioverter defibrillator, pacemaker or cardiac resynchronization device\n* Evidence of misuse, aberrant use, or addiction to alcohol or an illicitly used drug of abuse, or had a positive test for drugs of abuse\n* Inability to comply with any component of the study protocol\n* Younger than 18 or greater than 80 years old at the time of enrollment\n* Patient already on Suzetrigine\n* Allergy or contraindication to Suzetrigine or excipients (eg moderate to severe liver disease\u002FChild Pugh B or C, use of strong CYP3 inhibitors or inducers)\n* Contraindications to neuraxial anesthesia or any other part of the study protocol\n* Participation in another investigational drug or device study\n* Pregnancy",true,{"count":87,"type":21},210,[56],"Total hip and knee joint replacements are among the most common and painful orthopedic procedures performed worldwide, often requiring intensive analgesia to support early ambulation and recovery. Despite widespread use of multimodal regimens, many patients still rely on opioids, which can cause sedation, nausea, constipation, and long-term dependency. Evaluating Suzetrigine in this high-need population may improve recovery trajectories, reduce opioid consumption, and support enhanced recovery protocols. Given the growing surgical volume and the emphasis on opioid-sparing strategies, rigorous investigation of Suzetrigine's efficacy in joint replacement is of high clinical value. In this study, patients undergoing primary total hip replacement will be randomized to receive either Suzetrigine or placebo for seven days, with the loading dose administered prior to surgery. The primary outcome is cumulative 48-hour opioid consumption in oral morphine equivalents starting from entry into the post-anesthesia care unit (PACU).",[91,92,93,94,95,96,97,98,99,100,101,102,59,28,103,104,105],"Total Hip Arthroplasty (THA)","Total Hip Arthroplasty \\(THA\\)","Total Hip Replacement","Total Hip Replacement Surgery","Total Hip Replacements","Total Hip Replacement Arthroplasty","Suzetrigine","Pain Management","Pain","Nav 1.8","JOURNAVX","Opioid Cessation","Randomized Controlled Trial","Randomized Controlled Study","Randomized Controlled Trials","2026-06-02",{"date":108,"type":36},"2026-06-03",{"date":110,"type":36},"2025-11-03",{"date":112,"type":21},"2028-11-01",{"name":114,"class":42},"Hospital for Special Surgery, New York",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":123,"minAge":124,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":128,"conditions":129,"keywords":133,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":77},"100625777","phase-3-robotic-opioid-free-prostatectomy-enhanced-strategy-ropes-100625777","NCT07427043","Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)","Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES): Implementation of an Opioid-free Multimodal Analgesia Discharge Pathway","ROPES","Inclusion Criteria:\n\n* Men ≥45 years old\n* Undergoing Robotic Assisted Laparoscopic Prostatectomy (RALP) at BWH or BWFH\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Chronic kidney disease (baseline Cr \\>1.3)\n* NSAID contraindication\u002Fallergy\n* Regular opioid use or substance abuse prior to surgery\n* Inability to provide their own consent\n* Deviation from standard surgical practice for RALP (e.g. major complication requiring operative intervention that would result in patient no longer being considered a routine case)","MALE","45 Years",{"count":126,"type":21},300,[56],"This prospective, interventional, open-label, phase 3 randomized study evaluates a multimodal analgesia discharge pathway to reduce automatic opioid prescribing following routine robotic-assisted laparoscopic prostatectomy (RALP). Patients are counseled on post-operative pain management and then may opt into or out of the study with randomization to discharge prescriptions including (A) multimodal plan with additional automatic opioid prescription or (B) multimodal plan alone and instruction to call phone line to request opioid prescription if pain management is insufficient. Additionally, a cohort of historical controls prior to implementation of the study is also prospectively assessed as a pre-study baseline. The primary outcome is postoperative opioid consumption. Secondary outcomes include bowel function recovery, unplanned care encounters including emergency department visits or postoperative phone calls, and same-day discharge rates.",[59,28,130,131,132],"Robotic Assisted Laparoscopic Surgery","Robotic Assisted Laparoscopic Radical Prostatectomy","Prostate Cancer",[28,131,64,134,130],"Localized Prostate Cancer","2026-05-20",{"date":137,"type":36},"2026-05-22",{"date":139,"type":36},"2026-03-01",{"date":141,"type":21},"2027-04-30",{"name":76,"class":42},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":154,"conditions":155,"keywords":158,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":43},"100625516","phase-4-continous-infusion-of-nefopam-for-patients-undergoing-pancreatoduodenectomy-100625516","NCT07423650","Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy","Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy: A Randomized Controlled Double-Blind Trial","Inclusion Criteria:\n\n1. Patients scheduled for elective pancreatoduodenectomy surgery\n2. Agreed to participate in the study\n\nExclusion Criteria:\n\n1. Refusal to participate\n2. Emergency surgery\n3. Patients with neurological disorders or other muscular or psychiatric disorders that impede communication\n4. Known allergic reactions to the used medication\n5. Known hyperalgesia\n6. Chronic opioid consumption\n7. Patients that require reintervention in the first 48h postoperatively\n8. Patients with pancreaticogastrostomy",{"count":151,"type":21},93,[153],"PHASE4","The goal of this clinical trial is to determine whether continuous nefopam administration, as part of a multimodal analgesia strategy, reduces opioid consumption and improves patient satisfaction after pancreatoduodenectomy.\n\nThe main questions are:\n\nDoes nefopam administration reduce opioid consumption after pancreatoduodenectomy?\n\nDoes nefopam administration reduce postoperative pain levels after pancreatoduodenectomy?\n\nResearchers will compare two other analgesic strategies, namely continuous lidocaine infusion and epidural analgesia, to assess whether they lead to better outcomes.\n\nParticipants will complete the QoR-15 questionnaire and report their pain levels at predefined time points before and after surgery.",[156,98,157,28],"Pancreatoduodenectomy","Opioid Analgesia",[159,156,160,161],"Nefopam","Opioids","Multimodal analgesia","2026-03-19",{"date":164,"type":36},"2026-03-24",{"date":166,"type":21},"2026-03",{"date":168,"type":21},"2026-10",{"name":170,"class":42},"Iuliu Hatieganu University of Medicine and Pharmacy",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":187,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":43},"100626369","paravertebral-catheter-versus-epidural-analgesia-in-totally-minimally-invasive-esophagectomies-100626369","NCT07434739","PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies","PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies: a Randomized Controlled Trial","PACEMIE","Inclusion Criteria:\n\n* Patient requiring totally minimally invasive surgical esophagectomy (robot-assisted or not) with 2 Ivor-Lewis type approaches: laparoscopy for the abdominal approach and thoracoscopy for the thoracic approach.\n* Age ≥ 18 years old\n* Patient who has given written consent to participate in the trial\n* Socially insured patient\n* Patient willing to comply with all study procedures and duration\n\nExclusion Criteria:\n\n* \\- Intervention planned by open esophagectomy (laparotomy and\u002For thoracotomy)\n* 3-stage esophagectomy, McKeown type\n* Obesity with body mass index ≥ 35 kg.m-2 (due to the foreseeable difficulties arising from this BMI).\n* Pregnancy\n* Haemostasis trouble\n* ASA score \\> 3\n* Renal failure (eGFR \\\u003C 50 mL\u002Fmin)\n* Ongoing opioid use (\\>3 months prior to the day of surgery)\n* Contraindication to local anesthesia\n* Local infection\n* Inability to receive informed information\n* Person deprived of the liberty\n* Person benefiting from a system of legal protection (guardianship…)",{"count":180,"type":21},506,[24],"Esophageal cancer ranks as the seventh leading cause of cancer globally, with 604,100 new cases, and the sixth leading cause of cancer-related deaths worldwide.\n\nWhen applicable, surgery is the gold standard treatment for resectable oesophageal-esophagogastric junction cancer. The surgical technique requires both an abdominal approach and a transthoracic approach to resect the esophagus, perform the anastomosis, and allow optimal lymph node removal.\n\nSurgery Historically, esophagectomy was performed entirely through open surgery. This procedure was complex, associated with significant morbidity and mortality, as well as intense acute and chronic postoperative pain.\n\nIn this context, thoracic epidural analgesia (TEA) is the gold standard in the management of acute postoperative pain. It allows for opioid sparing and reduces postoperative pulmonary complications.\n\nIn order to reduce postoperative pain, facilitate postoperative recovery and limit postoperative complications, particularly respiratory complications, the minimally invasive approach has been proposed for several surgical indications. This principle has led to the development of hybrid esophagectomy, i.e. an abdominal approach by laparoscopy and a thoracic approach by right thoracotomy. An abdominal laparoscopic approach during esophagectomy, even in combination with a right thoracotomy, would therefore limit postoperative complications compared to open surgery.\n\nIn parallel to the wider use of hybrid esophagectomy, some teams have demonstrated the feasibility of a totally minimally invasive esophagectomy (TMIE), first video-assisted, then robot-assisted.\n\nThe rise of minimally invasive surgery (both hybrid and totally minimally invasive) has led to a decrease in postoperative pain compared to open surgery.\n\nEnhanced recovery after surgery protocols have been developed to improve postoperative recovery and management of acute postoperative pain. In this context, thoracic epidural analgesia TEA may prove counterproductive by inducing arterial hypotension requiring vasopressor drugs, acute urinary retention, and limiting mobilization. Moreover, thoracic epidural analgesia TEA failure occurs in 30% of cases. In minimally invasive surgery, it may be inadequate in half of the patients.\n\nParavertebral block (PVB) appears as a satisfactory alternative for postoperative analgesia management. In this sense, PVB is recommended for pain management in thoracoscopic lung.\n\nEvidence of the effectiveness and interest of the paravertebral catheter is lacking regarding totally minimally invasive esophageal surgery as most studies demonstrating the benefit of Paravertebral block PVB in esophageal surgery were retrospective.",[184,185,28,186],"Esophageal Cancer","Esophagectomy","Minimally Invasive Surgery",[188,161,189,190,191],"Minimally Invasive surgery","Paravertebral","Epidural","Esophagectomies","2026-02-19",{"date":194,"type":36},"2026-02-27",{"date":196,"type":21},"2026-05-01",{"date":198,"type":21},"2028-10-01",{"name":200,"class":42},"University Hospital, Lille",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":85,"sex":16,"minAge":17,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":43},"100579088","efficacy-and-safety-of-cocktail-of-ropivacaine-for-local-infiltration-analgesia-in-patients-undergoing-laparoscopic-cholecystectomy-100579088","NCT06819748","Efficacy and Safety of Cocktail of Ropivacaine for Local Infiltration Analgesia in Patients Undergoing Laparoscopic Cholecystectomy","Efficacy and Safety of Cocktail of Ropivacaine,sodium Bicarbonate and Dexamethasone for Incision Local Infiltration Analgesia in Patients Undergoing Ambulatory Laparoscopic Cholecystectomy:A Prospective Randomized Control Trial","Inclusion Criteria:\n\n* Patients undergoing daytime laparoscopic cholecystectomy in Sichuan Provincial People's hospital ② Age: 18-70 years\n\n  * American society of Anesthesiologists physical status classification system I-II ④ 18 kg\u002F㎡≤ BMI ≤ 30 kg\u002F㎡ ⑤ No communication barriers, able to understand the research process and the use of pain scale.\n\n    * Signed informed consent\n\nExclusion Criteria:\n\n* Drug allergy related to this study\n\n  * History of chronic pain, long-term use of analgesic drugs (equivalent to ≥ 10mg oxycodone per day), alcohol abuse, gastrointestinal bleeding or perforation after application of non steroidal anti-inflammatory drugs\n\n    * Patients with ischemic heart disease, peripheral arterial vascular or cerebrovascular disease, or patients with pulmonary heart disease, active peptic ulcer or gastrointestinal bleeding, or patients with inflammatory bowel disease\n\n      * Patients taking monoamine oxidase inhibitors or within 2 weeks after discontinuation ⑤ Preoperative pain score (NRS ) was greater than or equal to 4 points ⑥ Participated in other clinical studies within three months","70 Years",{"count":87,"type":21},[24],"The goal of this clinical trial is to learn if the use of cocktail of ropivacaine,sodium bicarbonate and dexamethasone for incision local infiltration analgesia in patients undergoing ambulatory laparoscopic cholecystectomy is safe and effective. The main questions it aims to answer are:\n\nDoes the cocktail lower the The incidence of moderate to severe pain during movement stages within six hours after surgery.\n\nResearchers will compare the cocktail to ropivacaine for incision local infiltration analgesia to see if the cocktail works to moderate the postoperative pain of ambulatory laparoscopic cholecystectomy patients.\n\nParticipants will:\n\nReceive the cocktail or ropivacaine for incision local infiltration analgesia at the end of the surgery.\n\nAnswer the questions about postsurgical pain at rest or during motion(using a Numeric Rating Scale (NRS) of 0 to 10. Pain measurements were performed at 2, 6, 12, 24 hours,3,7,30 days and 3 months postoperatively.",[213,214,28],"Cholecystectomy, Laparoscopic","Ambulatory Surgical Procedures","2025-02-16",{"date":217,"type":36},"2025-02-19",{"date":219,"type":36},"2025-02-14",{"date":221,"type":21},"2025-09-01",{"name":223,"class":42},"Sichuan Provincial People's Hospital",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":231,"maxAge":17,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":234,"briefSummary":235,"conditions":236,"keywords":240,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":43},"100559378","phase-4-magnesium-sulfate-in-children-undergoing-laparoscopic-appendectomy-100559378","NCT06563349","Magnesium Sulfate in Children Undergoing Laparoscopic Appendectomy","The Effect of Intravenous Magnesium Infusion on the Opioid Consumption, the Circulatory, Metabolic and Hormonal Response to Intubation and Surgical Trauma During Anaesthesia for Laparoscopy in Children. Randomized Clinical Trial.","Inclusion Criteria:\n\n* ASA (American Society of Anesthesiologists) physical status class 1E, 2E, 3E (E - emergency)\n* Patients undergoing laparoscopic appendectomy\n\nExclusion Criteria:\n\n* Allergy to the magnesium sulfate or the excipient\n* Hypermagnesemia\n* Renal failure (GFR \\\u003C30 ml\u002Fmin)\n* Myasthenia gravis\n* Preoperative atrioventricular block\n* Hypotension\n* The use of digitalis glycosides\n* The use of oral anticoagulants\n* ASA physical status class 4E or higher\n* Chronic treatment with analgesics\n* Legal guardians or patient refusal","18 Months",{"count":233,"type":21},188,[153],"Magnesium sulfate is one of the most commonly used co-analgetics. Its antinociceptive effect is related to antagonizing NMDA (N-methyl-D-aspartate) receptors of the nervous system, has an anti-inflammatory effect by reducing the concentration of IL-6 (interleukin 6) and tumor necrosis factor alpha. In adult patients, the need for morphine in the perioperative period is reduced when magnesium infusion is used. In current guidelines for treatment of acute pain in children, magnesium sulfate may be considered as a co-analgetic. However, the strength of such a recommendation is low due to the lack of reliable scientific research confirming the effectiveness of magnesium infusion in the pediatric population. The aim of this study is to evaluate the efficacy of intravenous magnesium sulfate infusion on the opioid consumption, the circulatory, metabolic and hormonal response to intubation and surgical trauma during anesthesia for laparoscopic appendectomy in children.",[237,28,238,239],"Opioid Consumption","Acute Appendicitis","Complication of Treatment",[241,242,243,244,245,246,247,248,249],"multimodal analgesia","magnesium sulfate","laparoscopic appendectomy","children","pediatric population","adjuvant","metabolic stress response","hormonal response","inflammatory response","2024-11-09",{"date":252,"type":36},"2024-11-12",{"date":254,"type":36},"2024-09-09",{"date":256,"type":21},"2027-10-01",{"name":258,"class":42},"Medical University of Warsaw",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":22,"phases":269,"briefSummary":270,"conditions":271,"keywords":276,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":4},"100556177","phase-4-effects-of-minimal-flow-sevoflurane-and-multimodal-analgesia-in-head-and-neck-cancer-surgery-100556177","NCT06521697","Effects of Minimal-Flow Sevoflurane and Multimodal Analgesia in Head and Neck Cancer Surgery","Anesthetic-sparing and Renal Protection Effects of Minimal-flow Sevoflurane Anesthesia and Multimodal Analgesia Using a Mixture of Dexmedetomidine-ketamine-lidocaine in Head and Neck Cancer Patients With Free Flap Microvascular Surgery","Inclusion Criteria:\n\n* Age 18-99 years\n* Scheduled for head and neck cancer tumor resection and free flap reconstruction surgery\n\nExclusion Criteria:\n\n* Preoperative tracheostomy\n* History of previous head and neck cancer tumor resection\n* Anemia (hematocrit \\\u003C30% or recent transfusion)\n* Hypertension on ACEI\u002FARB medications\n* Significant medical conditions (e.g., NYHA class 3 or 4 heart failure, eGFR \\\u003C60 ml\u002Fmin\u002F1.73 m², Child B or C liver failure, severe respiratory disorders, pre-existing cognitive impairment)\n* ASA physical status 4 or 5\n* Allergies to sevoflurane, dexmedetomidine, ketamine, or lidocaine","99 Years",{"count":268,"type":21},60,[153],"This study evaluates the anesthetic-sparing and renal protection effects of minimal-flow sevoflurane anesthesia combined with multimodal analgesia using dexmedetomidine, ketamine, and lidocaine in head and neck cancer patients undergoing free flap microvascular surgery. The 2x2 factorial randomized controlled trial aims to compare sevoflurane usage and renal function changes with different fresh gas flow rates and multimodal analgesia.",[272,273,274,275,28],"Head and Neck Cancer","Anesthesia","Renal Protection","Acute Kidney Injury",[277,278,279,161,272],"Greenhouse gas","Carbon emissions","Acute kidney injury","2024-07-21",{"date":282,"type":36},"2024-07-26",{"date":284,"type":21},"2024-08",{"date":286,"type":21},"2025-12",{"name":288,"class":42},"National Taiwan University Hospital"]